Phytomedicine:加味黄连解毒汤及其活性部位对小鼠模型的抗特应性皮炎作用

2022-08-17 紫菀款冬 MedSci原创

利用2,4-二硝基氯苯(DNCB)和卡泊三醇(MC903)致敏的特应性皮炎(AD)小鼠模型,开发加味黄连解毒汤(MHLJDD)并鉴定其活性成分作为AD的创新治疗剂。

背景:黄连解毒汤(HLJDD)是一种传统的中药配方,长期以来一直用于治疗包括特应性皮炎(AD)在内的炎症性皮肤病。由于栀子的肝肾毒性,该研究选用白鲜皮代替HLJDD组方中的栀子,希望得到具有更好安全性的加味HLJDD(MHLJDD)

目的:该研究旨在利用2,4-二硝基氯苯(DNCB)和卡泊三醇(MC903)致敏的AD小鼠模型,开发MHLJDD并鉴定其活性成分作为AD的创新治疗剂

方法:给DNCB诱导的小鼠和MC903诱导的小鼠灌胃MHLJDD以及1-丁醇可溶部分和水可溶部分的组合(MHLJD-F),为期两周。在整个研究过程中,测量了小鼠的体重、背部皮肤/耳朵厚度和AD症状的严重程度。药物治疗后观察抓挠行为。采集小鼠的血液和背部皮肤/耳组织进行组织病理学检查和生化分析。

结果:DNCB-和MC903诱导的AD症状,包括背部皮肤和耳朵的皮肤增厚、干燥、红斑和擦伤,在MHLJDD和MHLJD-F处理的小鼠中显著减轻

经MHLJDD和MHLJD-F处理后,丝聚合蛋白和loricrin的神经酰胺含量和蛋白质表达上调

DNCB和MC903诱导的皮肤炎症在MHLJDD和MHLJDF处理的小鼠中得到明显抑制,其作用机制包括抑制炎性细胞因子的释放,以及下调NF-κB和MAPKs通路的激活

MHLJDD和MHLJD-F可逆转DNCB诱导的小鼠肠道微生物群丰度

结论:MHLJDD和MHLJD-F可通过抑制NF-κB和MAPKs通路的激活和调节肠道菌群失调,改善表皮屏障功能和抑制皮肤炎症,从而显著缓解DNCB和MC903诱导的小鼠AD样症状。该研究首次报道了MHLJDD及其活性组分可作为AD的创新治疗剂。

 

文献来源:

Wang L, Hu Z, Yang W, et al. Anti-atopic dermatitis effect of a modified Huang-Lian-Jie-Du decoction and its active fraction on 2,4-dinitrobenzene and MC903-induced mouse models. Phytomedicine. 2022;104:154346. doi:10.1016/j.phymed.2022.154346

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1859289, encodeId=cee4185928993, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Nov 18 09:28:57 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774084, encodeId=93d91e74084a1, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Feb 02 07:28:57 CST 2023, time=2023-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436828, encodeId=1ef114368287e, content=<a href='/topic/show?id=a9424e199a5' target=_blank style='color:#2F92EE;'>#小鼠模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47199, encryptionId=a9424e199a5, topicName=小鼠模型)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Aug 16 14:28:57 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577917, encodeId=1fcf15e79170e, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Tue Aug 16 14:28:57 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611695, encodeId=22a21611695ea, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Aug 16 14:28:57 CST 2022, time=2022-08-16, status=1, ipAttribution=)]
    2022-11-18 jeanqiuqiu
  2. [GetPortalCommentsPageByObjectIdResponse(id=1859289, encodeId=cee4185928993, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Nov 18 09:28:57 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774084, encodeId=93d91e74084a1, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Feb 02 07:28:57 CST 2023, time=2023-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436828, encodeId=1ef114368287e, content=<a href='/topic/show?id=a9424e199a5' target=_blank style='color:#2F92EE;'>#小鼠模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47199, encryptionId=a9424e199a5, topicName=小鼠模型)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Aug 16 14:28:57 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577917, encodeId=1fcf15e79170e, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Tue Aug 16 14:28:57 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611695, encodeId=22a21611695ea, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Aug 16 14:28:57 CST 2022, time=2022-08-16, status=1, ipAttribution=)]
    2023-02-02 kalseyzl
  3. [GetPortalCommentsPageByObjectIdResponse(id=1859289, encodeId=cee4185928993, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Nov 18 09:28:57 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774084, encodeId=93d91e74084a1, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Feb 02 07:28:57 CST 2023, time=2023-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436828, encodeId=1ef114368287e, content=<a href='/topic/show?id=a9424e199a5' target=_blank style='color:#2F92EE;'>#小鼠模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47199, encryptionId=a9424e199a5, topicName=小鼠模型)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Aug 16 14:28:57 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577917, encodeId=1fcf15e79170e, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Tue Aug 16 14:28:57 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611695, encodeId=22a21611695ea, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Aug 16 14:28:57 CST 2022, time=2022-08-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1859289, encodeId=cee4185928993, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Nov 18 09:28:57 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774084, encodeId=93d91e74084a1, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Feb 02 07:28:57 CST 2023, time=2023-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436828, encodeId=1ef114368287e, content=<a href='/topic/show?id=a9424e199a5' target=_blank style='color:#2F92EE;'>#小鼠模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47199, encryptionId=a9424e199a5, topicName=小鼠模型)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Aug 16 14:28:57 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577917, encodeId=1fcf15e79170e, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Tue Aug 16 14:28:57 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611695, encodeId=22a21611695ea, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Aug 16 14:28:57 CST 2022, time=2022-08-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1859289, encodeId=cee4185928993, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Nov 18 09:28:57 CST 2022, time=2022-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774084, encodeId=93d91e74084a1, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Feb 02 07:28:57 CST 2023, time=2023-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436828, encodeId=1ef114368287e, content=<a href='/topic/show?id=a9424e199a5' target=_blank style='color:#2F92EE;'>#小鼠模型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47199, encryptionId=a9424e199a5, topicName=小鼠模型)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Tue Aug 16 14:28:57 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577917, encodeId=1fcf15e79170e, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Tue Aug 16 14:28:57 CST 2022, time=2022-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611695, encodeId=22a21611695ea, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Aug 16 14:28:57 CST 2022, time=2022-08-16, status=1, ipAttribution=)]

相关资讯

JEADV:Dupilumab治疗时出现面部皮炎需要特殊处理吗?

有研究中报道了使用 Dupilumab治疗的患者出现面部和颈部皮炎,我们对连续使用 Dupilumab的AD患者进行调查,描述其临床特征、形态和病因。

J Ginseng Res:人参皂苷提取物竟然具有治疗特应性皮炎的潜力

短期水培人参(sHCG)是在水培系统中培养4周的1年生人参幼苗,是一种具有多种生物学效应的功能性食品。本文对sHCG的最佳提取条件及其提取物的生物活性进行评估。

孙建方教授:生物制剂时代,传统药物治疗特应性皮炎仍有不可取代的优势

新型生物制剂为AD患者提供一个新的可供选择的治疗手段,疗效明确,但传统的治疗药物依然是治疗AD的重要手段。

华西皮肤论坛丨AD诊疗路径中关键要点中国共识解读

在2022年第五届华西皮肤论坛上,来自四川大学华西医院的王婷婷教授做了题为《AD诊疗路径中关键要点中国共识解读》的报道。

J Am Acad Dermatol:阿布昔替尼可有效治疗中度至重度特应性皮炎,无论之前患者对度匹鲁单抗的反应如何

在3期研究中,以前没有评估过中重度特应性皮炎患者的阿罗西尼疗效由先前的杜匹鲁单抗反应状态决定。

J Dermatolog Treat:阿布罗西尼可有效治疗特应性皮炎,且安全性可控

特应性皮炎(AD)是一种慢性复发性炎症性皮肤病。尽管皮质类固醇是治疗的基石,但Janus激酶抑制剂abrocitinib在最近的临床试验中显示出治疗AD的前景。